In our study, we aimed to investigate the role of CDR1as during competitive inhibition of miR-7 in the regulation of cisplatin chemosensitivity in breast cancer via regulating REGγ. RT-qPCR was applied to detect the expression of CDR1as and miR-7 in breast cancer tissues, breast cancer cell lines and corresponding drug-resistant cell lines.
| INTRODUC TI ON
Breast cancer, a class of heterogeneous malignant diseases, is the second leading cause of death among women, and different factors significantly affect its treatment and prognosis, including tumour size/grade and progesterone receptor status. 1, 2 Statistics revealed that 400 000 patients die from breast cancer each year, and approximately one million people are diagnosed with breast cancer around the world. 3 Additionally, breast cancer is the most common cancer in Chinese women, accounting for 12.2% of the total newly diagnosed breast cancers. 4 There are several factors that have been shown to induce breast cancer, including being overweight, alcohol consumption, physical inactivity, age at first birth, familial history and a long menstrual history. [5] [6] [7] For treatment, neoadjuvant and systemic chemotherapy are effective in breast cancer patients. 8 Furthermore,
cisplatin, an alkylated compound that can cause covalent DNA adducts resulting in cell death, is widely applied in the treatment of early and metastatic breast cancer. 9 However, resistance to chemotherapy remains a substantial obstacle in breast cancer treatment.
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Thus, the identification of factors associated with chemoresistance to cisplatin should enable the development of novel drugs for breast cancer treatment that do not respond to such treatment.
Circular RNAs (circRNAs), a novel class of non-coding RNA, are highly expressed in specific tissues and have a stable structure.
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CircRNAs regulate post-transcriptional or transcriptional gene expression by interacting with other molecules or microRNAs and potential biomarkers in several kinds of diseases, especially in cancers where they play an important role in cell proliferation, migration and invasion. [15] [16] [17] [18] CDR1as (also known as ciRS-7) acts as an oncogenic circRNAs mainly found in the human brain and is ∼1500 nucleotides in length. 19 Previous evidence found that CDR1as was involved in human tumourigenesis and dysregulated in various kinds of cancers. 20, 21 A recent study showed that CDR1as worked as a miR-7 sponge/inhibitor in the embryonic zebrafish. 22 In breast cancer, miR-7 worked as a tumour suppressor through blocking invasiveness and tumourigenic potential by targeting PAK. 23 REGγ (also known as PA28γ and PSME3), a nuclear protein, has been found in several kinds of human cancers, including breast cancer. 24 In particular, a high expression of REGγ might result in poor prognosis of breast cancer. 25 Thus, in our study, we first detected CDR1as expression in tissues and selected normal breast epithelial cells, breast cancer cells and drug-resistant breast cancer cells to investigate the effect of CDR1as on the regulation of cisplatin chemosensitivity in breast cancer with the involvement of miR-7 and REGγ.
| MATERIAL S AND ME THODS

| Ethical statement
The experiment was approved by an ethics committee of The Fifth People's Hospital of Wuxi, The Medical School of Jiangnan University, and all the participants signed the informed consent.
| Study participants
Between January 2014 and January 2018, 90 breast cancer patients enrolled in our hospital underwent neoadjuvant chemotherapy.
All patients were females with ages between 27 and 81 years old Before and after the neoadjuvant chemotherapy, all cases of CNB were examined by physical examination, coordinate mapping, breast B Ultrasound and molybdenum target to judge the curative effect.
Before the neoadjuvant chemotherapy, the size of the tumour after excision was measured by B-ultrasound, and the changes in the tumour were analysed. The curative effect was evaluated comprehensively combined with the biopsy and radical resection. The curative effect was as follows: complete remission (CR), no tumour was found by clinical means; partial remission (PR), reduction of the breast mass >50%; stable disease (SD), reduction of breast mass <50%, enlargement <25%; progressive disease (PD), enlargement of breast mass >25%; and CR + PR referred to the total effective rate. A total of 90 normal breast tissues were also collected as controls. All the breast cancer patients were first diagnosed. and incubated in a 5% CO 2 incubator at 37°C. The culture medium was changed every 3 days, and cell passage was performed after the cells reached 90% confluency. The adherent cells were detached by 0.25% trypsin, centrifuged and fresh culture medium was added for further incubation in a 5% CO 2 incubator at 37°C. Breast cancer cells at the logarithmic growth phase were selected and made into 5 × 10 7 cell suspensions. The cell suspension (10 mL) was inoculated into a culture bottle for 24 hours followed by addition of cisplatin (the final concentration was 10 nmol/mL) for further incubation for 48 hours. After incubation, the culture medium was discarded, and new culture medium was added for further incubation for 48 hours.
| Cell culture
After repeated culture, the concentration of cisplatin was gradually increased, and cell lines tolerant to 500 nmol/mL cisplatin were finally obtained and named MCF-7-R, SKBR-3-R, MDA-MB-231-R, MDA-MB-468-R and HCC-1937-R, which were cultured in complete culture medium containing 10 nmol/mL cisplatin. 
| Cell grouping
| Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Tissues or cells were collected for total RNA extraction via TRIzol.
Each sample (5 μL) was diluted 20 times with ultrapure water without the RNA enzyme, and the optical density (OD) value at 260 nm and 280 nm was recorded for determining the concentration and purity of RNA. The OD260/OD280 ratio between 1.7 and 2.1 indicated that the purity was high and could meet the needs of subsequent experimental research. The reverse transcription reaction was performed with the PCR amplifier to synthesize a cDNA template.
The real-time quantitative PCR experiment was carried out by the ABI7500 quantitative PCR instrument (PCR, ABI, Austin, TX, USA) with the reaction conditions as follows: pre-denaturation at 95°C for 10 min, 50 cycles at 95°C for 15 s, 60°C for 1 min and 72°C for 40 s.
The primers used are shown in Table 1 . The data were analysed by the 2 -ΔΔCt method. The experiment was repeated three times.
| Clonogenic assay
Cells in the logarithmic growth phase were detached with trypsin and lightly dissociated into a cell suspension using a straw. The cells were inoculated into 6-cm culture dishes with each culture dish containing 200 cells and incubated with complete culture medium containing 10 nmol/mL cisplatin in a 5% CO 2 incubator at 37°C for 2-3 weeks. During this period, the culture medium needed no replacement, and the culture was stopped when the clone was visible to the naked eye. With the culture medium discarded, the cells were washed two times with PBS, 5 mL methyl alcohol was added and allowed to stand at room temperature for 15 min. The fixation liquid was absorbed via a vacuum pump, and the Giemsa dye solution (SIGMA, USA) was added to the cells for 30 min. After the dye solution was discarded, the culture dish was air-dried. The number of clones was calculated directly by the naked eye and the clone formation rate was calculated.
| Cell counting kit-8 (CCK-8)
After treatment for 48 hours, the cells were detached and inocu- 
| Flow cytometry
After treatment for 48 hours, cells were collected, and the cell density was adjusted into 1 × 10 6 cells/mL. The cell suspension (0. 
| Western blot analysis
The 
| Dual luciferase reporter gene assay
The TargetScan database was used to analyse the binding sites between CDR1as and miR-7. The dual luciferase reporter gene assay was used to verify the targeting relationship between CDR1as and miR-7. The CDR1as linear sequence (CDR1as-WT) was cloned into the pmirGLO vector (Promega, Madison, WI, USA), and the sites that may interact with miR-7 were mutated to construct a mutant vector (CDR1as-MUT). The Renilla luciferase expression vector, pRL-TK (Takara company, Japan), was used as the control. The miR-7 mimic sequence and miR-7 NC sequence were cotransfected with CDR1as-WT and CDR1as-MUT into MCF-7 cells. The activity of the dual luciferase was detected following the manufacturer's instructions.
The experiment was repeated three times for each group.
The target genes of miR-7 were evaluated by the TargetScan database, and REGγ was selected as the direct target gene of miR-7.
The dual luciferase reporter gene assay was used to verify the targeting relationship between miR-7 and REGγ. The full length 3'UTR of REGγ was amplified (REGγ-WT), and the PCR product was cloned into the pmirGLO vector (Promega, Madison, WI, USA). The target gene database was used to predict the binding site between miR-7 and the target gene, and the sequence was then mutated a specific location (REGγ-Mut). The Renilla luciferase expression vector, pRL-TK (Takara company, Japan), was used as the control. The miR-7 mimic sequence and miR-7 NC sequence were cotransfected with
REGγ-WT and REGγ-Mut into MCF-7 cells. The activity of dual luciferase was detected following the manufacturer's instructions. The experiment was repeated three times for each group. 
| Subcutaneous xenograft nude mouse model
| Immunohistochemical staining
Sections of transplanted tumour tissues were obtained, and endogenous peroxidase was blocked with 30% H 2 O 2 . An antigen repair solution was added to the sections before boiling. After cooling for 5 min, the processes of boiling and cooling were repeated two times.
After cooling at room temperature, the sections were incubated with 5% BSA at room temperature for 20 min, followed by the removal of the excess liquid. Subsequently, the sections were incubated with 
| Statistical analysis
The data in our study were analysed using SPSS 22.0 software (SPSS, Chicago, IL, USA). All data are presented as the means ± standard deviation. Pairwise comparison was conducted using the least significant difference method, while multiple group comparison was performed via one-way ANOVA. Comparison between two groups of measured data from normal distribution was conducted using Student's t test, while correlation analysis of counting data was done using spearman method. P < 0.05 indicates a significant difference.
| RE SULTS
| Positive correlation between drug resistance and CDR1as expression in breast cancer
The CDR1as expression in breast cancer tissues and normal breast 
| CDR1as can increase the sensitivity of breast cancer-resistant cells to cisplatin
MCF-7-R and MDA-MB-231-R cells were transfected with si-CDR1as
and CDR1as plasmids, respectively, followed by treatment of differ- clusters corresponding to miR-7 sites. 26 The target gene of miR-7
| Low expression of miR-7 and high expression of REGγ in breast cancer-resistant cells
was evaluated using the TargetScan database, and REGγ was selected as the direct target gene of miR-7 ( Figure 3A) . REGγ expression were found in MCF-7-R and MDA-MB-231-R cells ( Figure 3D ).
F I G U R E 3
Expression of miR-7 and REGγ in drug-resistant breast cancer cells. Note: A, TargetScan predicted that REGγ was a target gene of miR-7; B, Identification of REGγ as a target gene of miR-7 by dual luciferase reporter gene assay; * P < 0.05 compared with the miR-7 NC group; C, The expression of miR-7 and REGγ in clinical tissues, 90 were normal breast tissues, 90 were breast cancer tissues before neoadjuvant chemotherapy and 66 were breast cancer tissues after neoadjuvant chemotherapy; * P < 0.05 compared with normal breast tissues; # P < 0.05 compared with breast cancer tissues before neoadjuvant chemotherapy; D, Expression of miR-7 and REGγ in breast cancer cell lines; # P < 0.05 compared with the relevant breast cancer parent cells
| CDR1as competitively inhibits miR-7 and upregulates REGγ expression
The analysis of the correlation between CDR1as and miR-7 expression in breast cancer tissues before chemotherapy revealed that the expression of CDR1as and miR-7 was negatively correlated ( Figure 4A ). In this study, we speculated that CDR1as may play a regulatory role in drug resistance of breast cancer by regulating miR-7. The bioinformatics software, TargetScan, analysis showed that CDR1as has miR-7 binding sites ( Figure 4B ). The dual luciferase reporter gene assay results showed that the miR-7 mimic could decrease luciferase activity in the CDR1as-Wt group, but did not affect luciferase activity in the CDR1as-MUT group, indicating that CDR1as competitively bind miR-7. miR-7 and REGγ expression in MCF-7-R and MDA-MB-231-R cells were detected by RT-qPCR and western blot analysis ( Figure 4D-F) . The result showed that compared with the blank group, increased miR-7 and decreased REGγ expression were found after transfection of si-CDR1as, while the opposite trend was found after transfection of CDR1as. It was further demonstrated that CDR1as could competitively inhibit miR-7
and up-regulate the expression of REGγ. showed that no significant difference was found in the clone formation rate between the NC and blank groups (P > 0.05). Compared with the NC group, the miR-7 mimic group had decreased clone formation rate, while the miR-7 inhibitor group had increased clone formation rate. Compared with the si-CDR1as group, the si-CDR1as + miR-7 inhibitor group had increased clone formation rate. The cell apoptosis rate results ( Figure 5D and E) revealed that compared with the NC group, the miR-7 mimic group had an increased cell apoptosis rate, while the miR-7 inhibitor group had a decreased cell apoptosis rate. Compared with the si-CDR1as group, the si-CDR1as + miR-7 inhibitor group had decreased cell 
| Inhibition of miR-7 can reverse the enhanced sensitivity of silenced CDR1as to drug-resistant breast cancer cells
| D ISCUSS I ON
The treatment of breast cancer has been developed from the initial surgical method on local area control to multidisciplinary management, focusing on systemic treatment, thus significantly improving survival rates. 27 However, the response of breast cancer patients to chemotherapy is very different, despite the initial clinical response, patients developed a certain degree of resistance. 28 In our study, CDR1as was found to be highly expressed in 90 breast cancer patients. Further analysis in breast cancer cells revealed that silencing of CDR1as increased miR-7 expression, inhibited REGγ expression and enhanced the sensitivity of drug-resistant breast cancer cells to cisplatin.
Previous evidence has shown that circRNAs are highly expressed and evolutionarily conserved across the eukaryotic tree of life, thus, indicating potential biological functions.
29
Additionally, reports revealed that circRNAs may be involved in to decreased Caspase-3 activity and apoptosis, 36 which were consistent with our findings. Furthermore, we also concluded that miR-7 expression was low, and REGγ was highly expressed in breast cancer drug-resistant cells. miR-7 is reported to be a tumour suppressor miRNA in various kinds of malignancies such as breast, head and neck and colon. 23, 37, 38 The conclusions obtained from previous study also proved that the overexpression of miR-7 might serve as a suitable method for the treatment of highly invasive breast cancer.
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In addition, REGγ has been found in several types of human cancer, and high expression of REGγ as correlated with metastasis and poor prognosis of breast cancer patients. 25 circRNAs could regulate gene expression at different levels by interacting with different DNA, miRNA, lncRNA or proteins to modulate different kinds of cell physiological and pathological processes. 40, 41 Furthermore, we also found that CDR1as competitively inhibits miR-7 and down-regulates REGγ expression, and inhibition of miR-7 can reverse the enhanced sensitivity of silenced CDR1as to drug-resistant breast cancer cells. Partly in line with our study, miR-7
was also found to regulate cetuximab sensitivity, and lowly expressed miR-7 was regarded as an independent prognostic factor for poor survival of patients with colorectal cancer. 42 REGγ plays an important role in breast cancer through inducing proteolysis with up-regulated expression found in breast cancer, and REGγ was negatively correlated with miR-7-5p. 24 Ectopic expression of CDR1as may trigger midbrain brain defects, which was similar to the phenotypes discovered in the knockdown of miR-7. 29 Additionally, the expression of CDR1as was inversely related to miR-7 expression in HCC tissues.
33
This study demonstrated that CDR1as overexpression is associated with adverse chemotherapeutic effects and that CDR1as competitive inhibition of miR-7 enhanced the sensitivity of drugresistant breast cancer cells to cisplatin. In addition, we found that
REGγ was a direct target of the CDR1as/miR-7 axis, and REGγ was positively associated with CDR1as expression in breast cancer samples. Based on these observations, we suggested that the aberrant CDR1as/miR-7 axis may serve as a promising target for finding novel therapies to alleviate drug resistance in breast cancer.
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